Find the Best Available Evidence

 Quick Analysis Plan Copied

 Long Analysis Plan

The supplied evidence does not answer the exosomal question

None of the seven supplied studies measured exosomes, extracellular vesicles, or EV cargo (e.g., CD9, CD63, CD81, TSG101, miRNA content). I cannot cite exosomal markers of successful HIIT from these records, and I will not confabulate them. What the records do support are circulating/plasma markers that track HIIT success and would be rational candidates to test in EV fractions:

• PGC-1α: plasma PGC-1α rose 63% with HIIT vs 33% without (P=0.047), a mitochondrial-biogenesis readout HIIT raises plasma PGC-1α.
• IL-6 (rat model): 6-week HIIT lowered serum IL-6 (2584±697 pg/mL) vs MIT and control (P≤0.003) HIIT lowers IL-6 in obese rats.
• BDNF and irisin: increased only in the HIIT group of 12-week-trained elderly women HIIT raises BDNF/irisin in elderly women.
• Functional success markers: VO2 kinetics (τp 56→~42 s) and VO2peak gains (~31–35%) converge by week 3 in both HIIT and MICT HIIT speeds VO2 kinetics in T2D, with meta-analytic HIIT-vs-control SMDs of 0.57–1.81 across populations Meta-analysis of HIIT VO2max gains.

Analysis plan: (1) Use the above as plasma-level outcomes defining "successful HIIT" responders (VO2peak change, VO2 kinetics, PGC-1α, BDNF/irisin, IL-6). (2) In a future trial, isolate plasma EVs (SEC + anti-CD63/CD81 capture), quantify EV surface markers by flow cytometry/NTA, and run EV small-RNA-seq and proteomics; correlate EV cargo shifts with the responder phenotypes. (3) In Python (scanpy/anndata-style pipelines, statsmodels for ANCOVA adjusted for baseline), test whether EV miRNA/protein changes predict VO2peak response beyond training volume. These are plans, not evidence—the exosomal link remains untested here.

What would change this conclusion: any controlled study measuring EV-isolated cargo before/after HIIT showing cargo changes tracking VO2peak gains would establish exosomal markers; none is present in the supplied records.